ArticlePathology oncology research : POR2012
Serum amyloid a protein in clinical cancer diagnosis.
Article in Pathology oncology research : POR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- MRI and Biomarkers in Early Detection of Pulmonary Changes in Ataxia-Telangiectasia.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Ionising radiation exposure-induced regulation of selected biomarkers and their impact in cancer and treatment.Frontiers in nuclear medicine · 2024Review
- Identification of SAA1 as a novel metastasis marker in ovarian cancer and development of a graphene-based detection platform for early assessment.Journal of cancer research and clinical oncology · 2023Article
- Serum Extracellular Vesicle Stratifin Is a Biomarker of Perineural Invasion in Patients With Colorectal Cancer and Predicts Worse Prognosis.Frontiers in oncology · 2022Article
- Stress Response Is the Main Trigger of Sporadic Amyloidoses.International journal of molecular sciences · 2021Review
- Trained Immunity for Personalized Cancer Immunotherapy: Current Knowledge and Future Opportunities.Frontiers in microbiology · 2019Review
- Household coal combustion, indoor air pollutants, and circulating immunologic/inflammatory markers in rural China.Journal of toxicology and environmental health. Part A · 2019Article
- Review
- SAA1 polymorphisms are associated with variation in antiangiogenic and tumor-suppressive activities in nasopharyngeal carcinoma.Oncogene · 2015Article
- Inflammation: an important parameter in the search of prostate cancer biomarkers.Proteome science · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The serum amyloid A (SAA) protein is an acute phase protein that is synthesized under the regulation of inflammatory cytokines during both acute and chronic inflammation. It is suggested that the SAA increases correlate with many types of carcinogenesis and neoplastic diseases. Th changes in SAA in serum could therefore indicate the progress and malignancy of the disease, as well as the host responses. The present paper reviewed the rationale of using SAA as potential cancer biomarker in clinical diagnosis, including the contribution and involvement of SAA in cancer growth and development. Then we discussed the current applications of SAA in diagnosis and tracing of different types of cancers. Finally the proteomics techniques, especially the SELDI-TOF MS to identify SAA in serum from patients were appreciated as an important manner in clinical diagnosis.
Indexed as
Identifiers
21901273What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.